How do Italian biotechnology startups survive? by Nosella, A. (Anna) et al.
      Journal of Business Chemistry Vol. 3, Issue 2 May 2006 
         
 
 













Anna Nosella*, Giorgio Petroni* and Chiara Verbano*# 
 
* Dip. Tecnica e Gestione dei Sistemi Industriali, Università degli Studi di Padova, Str.lla San Nicola 3, 36100 
Vicenza, Italy 
# Correspondence to: chiara.verbano@unipd.it 
   
 
 
Abstract: This study was carried out in order to better understand the economic and managerial 
characteristics of the biotechnology industry, which has taken hold in Italy at a much slower rate than in other 
industrialized countries. In particular, the specific aims of this paper are to analyse the business models of 
new Italian biopharmaceutical firms and to examine how these firms, with their different business models, 
successfully overcome the initial stage of starting up. On the basis of interviews conducted with sector 
experts and managers, we will conclude that the success factors behind the startups comprise a diverse range 
of distinct competencies that depend on the type of business model adopted. 
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Introduction 
Biotechnology is one of the most significant 
emerging technologies and generates many 
applications in different fields, such as healthcare, 
agriculture, the food industry, fine chemistry and 
the environment.  
The biotechnology industry was pioneered in 
the Unites States where small biotechnology firms 
were started up in the early 1980s; the 
development of the biotechnology industry, 
however, has not been uniform in all countries. In 
Europe, with the sole exception of the United 
Kingdom, the business of biotechnologies 
developed much later than in the United States 
due to the following main reasons [1, 2]: 
 
• The problem of finding financing for these 
new firms (in particular the absence of a 
structured venture capital system) 
• The limited protection guaranteed by the 
patents system 
• The weak relationship between Academia 
and Industry, which complicates the 
knowledge transfer process 
• The fragmentation and specialization of 
research. 
 
As in other European countries, the 
development of the biotechnology industry has 
taken hold in Italy only recently; in fact, even 
though there is a good level of scientific and 
technical competency, particularly in the 
pharmaceutical industry [3], the factors mentioned 
above have delayed growth. 
In the pharmaceutical sector, in particular, 
biotechnology is doomed to undergo a revolution 
that will change the industry’s structure: on one 
hand a process of concentration of large firms has 
begun to take place and on the other hand new 
small biotechnology firms specialising in a 
particular discipline or research activity have been 
launched.  
As a consequence, the biopharmaceutical sector 
is organized as a network made up of universities, 
public and private research centres, small 
biotechnology companies and large consolidated 
companies all working in collaboration rather than 
in competition.  
The first aim of this paper is to analyse the 
different business models adopted by the 
companies that constitute this network; in 
identifying this taxonomy of business models, 
particular attention was paid both to the value 
chain activities of these companies and to the 
products and services they exchange with the 
market. We expected some of the critical factors 
for competition to depend on the type of business 
model adopted. The second aim of this paper is to 
analyse the following issue: for each of the 
business models identified, we have examined one 
biopharmaceutical startup firm in order to study 
the critical factors that have allowed it to survive 
and compete in this context. In other words, we 
are interested in examining how new 
biopharmaceutical firms with different business 
models successfully overcome the initial stage of 
starting up.   
In order to identify the business models 
adopted by biotechnology companies, we first 
analysed the specialised literature [4, 5] and then 
confirmed the results obtained from the literature 
review by interviewing some sector experts (e.g. 
the head of the National Association for the 
Development of Biotechnology).   
Concerning the second objective of the study, 
which was to analyse the success factors of 
biopharmaceutical firms, we conducted eight 
interviews both with the CEO of these firms and 
with their R&D managers. The main topics 
discussed regarded: 
 
• The firm’s history: particular attention was 
given to the problem of finding financing 
• The firm’s offering: type of 
products/services, characteristics of the 
pipeline, production strategy (internal 
manufacturing/outsourcing/licensing), 
type of distribution 
• Market factors: nature of the market (local, 
national or international), position of the 
customer in the value chain, market 
breadth 
• Internal capability factors: the source of 
internal competence was identified 
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• Competitive strategy factors: the position 
of the firms in the competitive arena was 
analysed 
• Innovative performance of the firm: trend 
of R&D investments, number of patents 
obtained, trend of employees, number of 
products/ processes/ services being 
employed. 
 
The Business Models of  
Biopharmaceutical Companies  
Biotechnology has contributed to a change in 
the pharmaceutical sector in both the internal 
processes and the external industrial structure [4]. 
Concerning the former, the use of biotechnology 
has modified the research methodology and the 
production processes.  
Concerning the latter, biotechnology has 
changed the role played by pharmaceutical 
companies by creating a network of firms 
specialized in different activities along the value 
chain. Consequently, the pharmaceutical industry 
has taken a new configuration: while until the late 
eighties the sector was constituted by large 
vertically integrated companies, now it comprises a 
system of companies specialized in a particular 
stage of the innovative process, in a particular 
discipline, or in supplying services. The structure 
of this industry has become more complex and 
consequently different business models are 
adopted by biopharmaceutical firms. One of the 
aims of this paper is to suggest a taxonomy of 
these different business models on the basis of 
literature analysis [4,5] and the interviews 
conducted.  
Five different business models were identified: 
 
• New biotechnology firms: typically carry 
out research activities until lead 
optimisation, and then license their outputs 
(i.e. drug candidates) to other firms 
• Integrated firms: have a strong pipeline 
and carry out all the primary activities of 
the value chain, from target identification 
or lead optimisation to product 
commercialization. They thus cover the 
research and development phase, pre-
clinical and clinical development, the post-
approval phase, and production and 
commercialization activities 
• Manufacturing companies: typically acquire 
the results of the research carried out by 
other companies and dedicate their efforts 
to the latter phases of the innovative 
process by carrying out engineering, 
production and commercialization 
activities 
• Biotech suppliers: are firms that carry out 
the industrial development and production 
of biotech products for other firms. These 
companies use biotechnology in the 
production process in order to obtain 
biological products, such as monoclonal 
antibodies, cells and proteins, and supply 
them to other biotechnological companies. 
They develop production processes often 
in collaboration with customers and end 
their role with the supply of the product 
• Services firms: sell research services such 
as chemical synthesis, the study of cloning, 
and sequencing to drug-oriented 
companies that want to enhance their 
organisational competences. The startup 
capital required from this type of firm is 
smaller than that required by the previous 
business models. 
 
Literature analysis enabled us to recognize the 
following business models: new biotechnology 
firms, integrated firms, manufacturing firms and 
service firms. We decided to exclude platform 
firms (also identified in the cited literature) because 
their core business is constituted by developing 
and commercializing technologies (i.e. physical 
devices and software tools) to support the R&D 
process behind new drugs. The business model 
represented by biotech suppliers was identified 
through the interviews that at the same time were 
also used in order to confirm the previous 
business models. 
After identifying this taxonomy, we selected 
one Italian startup firm for each of the 
aforementioned business models with the aim of 
analysing the success factors which have allowed 
them to   overcome the startup stage. The firms 
selected were the following: 
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• Company  A, founded in 1998 from a 
previous industrial unit, is a new 
biotechnology firm (NBF) whose core 
business is focused on discovery and 
preclinical development stages. While this 
study was being carried out, the firm was 
involved in a merger process. 
• Company  B  was founded in 1996 after a 
“management buyout” with the aim of 
becoming an integrated firm. It operates in 
all value chain activities, from the research 
stage to product manufacture and 
commercialization. When this study was 
being carried out, the firm had already built 
the production plant, but it still hadn’t set 
up a network for commercializing its own 
products (which were currently in the 
second clinical stage). 
• Company  C,  founded in 1999, is a firm 
that carries out customized production for 
other companies. It uses biotechnology as 
a production methodology in order to 
develop biological products such as cells 
and monoclonal antibodies. 
• Company  D, founded in 2001, provides 
services (such as sequencing, diagnostic 
tests, training, etc.) in the field of 
diagnostics and research to firms belonging 
to different industries.  
 
Manufacturing companies have not been 
considered in this analysis because in the database 
[6] available on the Italian biotechnology industry 
there are no start-up firms that belong to this type 
of business model in Italy. 
The four firms considered in this study 
successfully overcame the startup stage as the most 
used performance indexes [7, 8, 9] highlighted:  
 
• Increase in R&D investments 
• Increase in the number of employees 
• Number of patents obtained 
• Number of products/processes/services 
being developed. 
 
At this point, it is interesting to identify the 
success factors that have allowed these firms to 
overcome the startup stage successfully; in this 
way, a connection is made between success factors 
and business models.  
 
The Success Factors of  
Biopharmaceutical Startup Firms  
The resource-based view represents the 
theoretical framework that has been adopted in 
this study in order to identify success factors; 
particular attention was then given to the set of 
resources and competences developed by the 
firms. In particular, resources were defined as 
stocks of available factors that are owned or 
controlled by the firm [10], while competence was 
defined as “the collective knowledge of an 
organization”, and in particular, “the capacity for 
the team of resources to perform some tasks or 
activities” [11]. 
While analyzing competences, it emerged that 
their nature changed according to the type of 
business models adopted. 
In case A, although technical-scientific know-
how is very important for the development of new 
products, managerial competences also play a 
fundamental role in the success of the startup; 
indeed, the study identified the following as the 
most important managerial skills:  
 
• Ability to choose profitable research 
projects 
• Management of human resources 
• Creation of an efficient collaboration 
network 
• Ability to find financial resources.  
 
While this study was being carried out, Firm B 
was in a similar situation to Firm A because it 
carried out research and clinical development, even 
though it had built the production plant and was 
setting up a sales network. In this case, technical 
know-how (mainly combinatorial chemistry and 
high throughput screening) and managerial 
competences are the most important success 
factors for firm B as well. Concerning managerial 
competences, the skills that emerged from the 
analysis are the following:  
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• Ability to absorb complementary 
knowledge from alliances 
• Management of human resources 
• Ability to manage post-approval activities 
• Ability to find financial resources. 
 
The literature [12, 13] sustains that production 
and marketing skills are fundamental for the 
success of integrated biopharmaceutical firms, but 
at this point these skills cannot be examined 
because of the young age of the companies. 
Firm C focused on quality excellence as the 
fundamental guiding force behind all these 
activities. From the startup phase, the 
management’s efforts were geared towards the 
implementation of a set of procedures and 
practices (e.g. the good manufacturing practices 
system) that ensure the manufacture of high 
quality products. The efforts of this firm’s 
management were devoted to the creation of a 
culture of organization focused on quality 
excellence and many activities (weekly meetings, 
training programs, team building) were 
implemented for this purpose. 
Firm D overcame the startup phase by 
developing a tight network of relationships with 
many different external partners, which allowed 
the firm to widen its range of services, increase its 
technical knowledge and strengthen its customer 
portfolio. The firm’s management guided its 
activities to overcome its present confines in order 
to create a new organizational configuration: a 
network of firms, with units comprising different 
organizations, such as research institutes, 
customers, diagnostics laboratories, universities, 
etc. Even the attention given to customers 
emerged  as a critical element for the success of 
the startup. 
Finally, it is important to underline that all the 
firms considered were founded by people who had 
previously worked for multinational firms and thus 
had substantial technical and managerial 
experience in this industry. In all the firms 
analysed, many different organizational processes 
have been activated by the management in order 




This study on the one hand identifies a 
taxonomy of business models in the 
biopharmaceutical industry and on the other hand 
shows how four biotechnology startups overcame 
the startup stage successfully. As illustrated above, 
startup success factors encompass a diverse range 
of distinct competences according to the type of 
business models adopted. Table 1 shows the 
success factors associated with each business 
model: 
In other words, this case analysis illustrates that 
the success elements are connected with the firm’s 
strategic value chain activities. 
In the case of new biotechnology firms, where 
research activities play a critical role in success, 
specific technical and scientific know-how (e.g. in 
target identification/validation, or in lead 
identification/optimization) is fundamental.  
In the case of integrated firms, where different 
value chain activities can play a critical role in 
success, both technical and scientific know-how, 
as well as an ability to perform approval activities 
and production and marketing competences, are 
important.  
In the case of services firms, where the most 
important activities are located at the end of the 
value chain, the ability both to satisfy customers 
and to establish many relationships with different 
organizations are strategic for success.  
Finally in the case of firms that carry out 
industrial development and production for other 
firms,  the ability to guarantee excellence in final-
product quality is the most important element for 
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Type of business models Success factors 
New biotechnology firm Scientific and technical know-how 
Managerial competences 
Integrated firm Scientific and technical know-how 
Managerial competences 
(production and marketing skills are 
hypothesized) 
Service firm Network relationships 
Attention to customers 
Biotech suppliers Excellence in quality of products 
 
Table 1: The success factors for each business model analyzed 
It is interesting to point out that, as Table 2 
shows managerial competences played a 
fundamental role in the success of all the startups 
examined regardless of the type of business 
models adopted; management of human resources, 
the ability to build and manage a network and 
implementation of the quality system are some 
examples of the managerial competences required. 
In all the cases analysed, these competences are 
generated by the founders who had accrued 
significant experience in this industry. 
The results of the study confirm the recent 
literature on this topic. In fact many studies [14, 
15, 8] have maintained the importance of inter-
organizational relationships, e.g. networks that 
generate new knowledge and create competitive 
advantage. Even the role of technical competence 
in the success of biopharmaceutical firms has long 
been recognized by many Authors [12, 16, 13]; 
Pisano [17] in particular stressed the role of the 
production process to guarantee a quality product.  
If, on one hand, the role of technical competence 
is fundamental, on the other hand managerial 
competence can also play a significant role in the 
success of biotechnology firms [18, 2]. 
The study is original in that it concerns the 
identification of different strategic competences 
according to the type of business model adopted. 
The suggestion emerging from this study is very 
important in particular for academic startups, 
where managerial skills are usually lacking in the 
scientific staff working at the university; for this 
reason the assistance given by technology transfer 
offices or other local authorities, in terms of 
organizational and financial support, could be very 
important.  
In particular in Italy, where there are very few 
university spin-offs in the field of biotechnology, 
an interesting solution to joint scientific and 
managerial competencies could be the launch of 
university startups where the founders are a team 
of both academic scientists and industry managers. 
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Type of business models Managerial competences 
New biotechnology firms - ability to choose profitable research 
projects;  
- management of human resources;  
- creation of an efficient collaboration 
network; 
- ability to find financial resources.  
 
Integrated firms - ability to absorb complementary 
knowledge from alliances; 
- management of human resources; 
- ability to manage post-approval activities;  
- ability to find financial resources. 
Service firms - ability to manage a network of different 
relationships; 
- ability to satisfy customers. 
Biotech suppliers - creation of a culture of organization  
focused on quality excellence. 
 
Table 2: The most important managerial competences for each of the business models analyzed 
Finally, a look at the study conducted by 
Weisenfeld-Schenk [19], who proposed a typology 
of biotechnology firms based on the strategic types 
described by Miles & Snow, reveals some 
similarities and suggestions for further research. 
The Weisenfeld-Schenk study classifies 
biotechnology firms into three main groups: the 
first group is constituted by companies that 
“pursue process improvements and are lowest on 
new product development”; the second group 
encompasses companies that are mainly devoted 
to basic research instead of applications 
engineering; and the third group is the closest to 
the market and between the first and second 
groups. Looking at this classification, we can see, 
for example, that cluster 2 described by 
Weisenfeld-Schenk seems to share some common 
points with the new biotechnology firms presented 
in our study. Further research could then 
investigate the strategic behaviour of 
biotechnology firms through a quantitative analysis 
that takes into consideration both the strategic 
types suggested by Weisenfeld-Schenk and our 
own findings about business models. 
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